JP2022500456A5 - - Google Patents
Info
- Publication number
- JP2022500456A5 JP2022500456A5 JP2021514419A JP2021514419A JP2022500456A5 JP 2022500456 A5 JP2022500456 A5 JP 2022500456A5 JP 2021514419 A JP2021514419 A JP 2021514419A JP 2021514419 A JP2021514419 A JP 2021514419A JP 2022500456 A5 JP2022500456 A5 JP 2022500456A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal form
- compound
- cancer
- chemical formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731500P | 2018-09-14 | 2018-09-14 | |
| US62/731,500 | 2018-09-14 | ||
| PCT/IB2019/057720 WO2020053816A1 (en) | 2018-09-14 | 2019-09-12 | Crystalline forms of a quinazole compound and its hydrochloride salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500456A JP2022500456A (ja) | 2022-01-04 |
| JP2022500456A5 true JP2022500456A5 (enExample) | 2022-09-22 |
| JP7554030B2 JP7554030B2 (ja) | 2024-09-19 |
Family
ID=69776732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514419A Active JP7554030B2 (ja) | 2018-09-14 | 2019-09-12 | キナゾリン化合物及びその塩酸塩の結晶形 |
| JP2021513941A Pending JP2022500416A (ja) | 2018-09-14 | 2019-09-12 | がんを処置するためのキットおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513941A Pending JP2022500416A (ja) | 2018-09-14 | 2019-09-12 | がんを処置するためのキットおよび方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220040180A1 (enExample) |
| EP (2) | EP3849964A4 (enExample) |
| JP (2) | JP7554030B2 (enExample) |
| KR (2) | KR20210061371A (enExample) |
| CN (2) | CN112823153A (enExample) |
| AR (2) | AR116669A1 (enExample) |
| AU (2) | AU2019337640A1 (enExample) |
| BR (2) | BR112021004527A2 (enExample) |
| CA (2) | CA3110369A1 (enExample) |
| IL (2) | IL281168A (enExample) |
| MX (2) | MX2021002876A (enExample) |
| PH (2) | PH12021550432A1 (enExample) |
| PY (2) | PY1976960A (enExample) |
| SG (2) | SG11202102006YA (enExample) |
| TW (2) | TW202027750A (enExample) |
| UY (2) | UY38374A (enExample) |
| WO (2) | WO2020056156A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021004527A2 (pt) | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
| PE20252386A1 (es) | 2019-11-21 | 2025-10-10 | Pharma Mar Sa | Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina |
| CN114642728A (zh) * | 2021-06-02 | 2022-06-21 | 德琪(浙江)医药科技有限公司 | mTOR抑制剂的制药用途及其药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596869B1 (en) * | 2003-01-21 | 2014-06-04 | New Form Pharmaceuticals Inc. | Novel cocrystallization |
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| KR20070107151A (ko) * | 2005-02-26 | 2007-11-06 | 아스트라제네카 아베 | 티로신 키나제 억제제로서의 퀴나졸린 유도체 |
| CN101454302A (zh) * | 2006-05-31 | 2009-06-10 | 艾博特公司 | 用作大麻素受体配位体的噻唑化合物及其用途 |
| CA2659307A1 (en) | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
| ES2573931T3 (es) * | 2007-02-21 | 2016-06-13 | Natco Pharma Limited | Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| KR101272613B1 (ko) | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
| EP2964638B1 (en) * | 2013-03-06 | 2017-08-09 | Astrazeneca AB | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
| CN106068262B (zh) * | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
| US10308658B2 (en) * | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| US11672801B2 (en) * | 2016-10-19 | 2023-06-13 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| BR112021004527A2 (pt) | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
-
2019
- 2019-09-12 BR BR112021004527-9A patent/BR112021004527A2/pt not_active Application Discontinuation
- 2019-09-12 KR KR1020217010772A patent/KR20210061371A/ko not_active Withdrawn
- 2019-09-12 AU AU2019337640A patent/AU2019337640A1/en not_active Abandoned
- 2019-09-12 KR KR1020217010957A patent/KR102802129B1/ko active Active
- 2019-09-12 AU AU2019340598A patent/AU2019340598B2/en active Active
- 2019-09-12 SG SG11202102006YA patent/SG11202102006YA/en unknown
- 2019-09-12 JP JP2021514419A patent/JP7554030B2/ja active Active
- 2019-09-12 US US17/275,290 patent/US20220040180A1/en not_active Abandoned
- 2019-09-12 MX MX2021002876A patent/MX2021002876A/es unknown
- 2019-09-12 WO PCT/US2019/050843 patent/WO2020056156A1/en not_active Ceased
- 2019-09-12 EP EP19859287.5A patent/EP3849964A4/en active Pending
- 2019-09-12 US US17/275,382 patent/US11883402B2/en active Active
- 2019-09-12 SG SG11202101712XA patent/SG11202101712XA/en unknown
- 2019-09-12 WO PCT/IB2019/057720 patent/WO2020053816A1/en not_active Ceased
- 2019-09-12 CA CA3110369A patent/CA3110369A1/en active Pending
- 2019-09-12 JP JP2021513941A patent/JP2022500416A/ja active Pending
- 2019-09-12 CN CN201980060170.XA patent/CN112823153A/zh active Pending
- 2019-09-12 MX MX2021002875A patent/MX2021002875A/es unknown
- 2019-09-12 CN CN201980060160.6A patent/CN112770758A/zh active Pending
- 2019-09-12 EP EP19860538.8A patent/EP3849557A4/en not_active Withdrawn
- 2019-09-12 BR BR112021004546-5A patent/BR112021004546A2/pt not_active IP Right Cessation
- 2019-09-12 CA CA3111062A patent/CA3111062A1/en active Pending
- 2019-09-16 UY UY0001038374A patent/UY38374A/es unknown
- 2019-09-16 AR ARP190102610A patent/AR116669A1/es not_active Application Discontinuation
- 2019-09-16 PY PY201901976960A patent/PY1976960A/es unknown
- 2019-09-16 UY UY0001038375A patent/UY38375A/es not_active Application Discontinuation
- 2019-09-16 TW TW108133290A patent/TW202027750A/zh unknown
- 2019-09-16 TW TW108133291A patent/TW202023562A/zh unknown
- 2019-09-16 AR ARP190102611A patent/AR116406A1/es not_active Application Discontinuation
- 2019-09-16 PY PY201901976957A patent/PY1976957A/es unknown
-
2021
- 2021-03-01 IL IL281168A patent/IL281168A/en unknown
- 2021-03-01 PH PH12021550432A patent/PH12021550432A1/en unknown
- 2021-03-01 IL IL281167A patent/IL281167A/en unknown
- 2021-03-03 PH PH12021550456A patent/PH12021550456A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7710356B2 (ja) | ５，１０－メチレン－（６ｒ）－テトラヒドロ葉酸のヘミ硫酸塩 | |
| ES2702450T3 (es) | Derivados de la quinoxalina útiles como moduladores de la FGFR quinasa | |
| JP6905662B2 (ja) | 置換キノリン化合物の結晶形およびその医薬組成物 | |
| JP2022500456A5 (enExample) | ||
| JP2020514271A5 (enExample) | ||
| AU2019218186B2 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| JP2010525057A5 (enExample) | ||
| JP2009515992A5 (enExample) | ||
| CA2917096A1 (en) | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors | |
| NZ739185A (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| JP2010523700A5 (enExample) | ||
| JP2018533608A (ja) | 置換キノリン化合物の結晶形およびその医薬組成物 | |
| JP2012518598A5 (enExample) | ||
| JP2018529643A5 (enExample) | ||
| JP7554030B2 (ja) | キナゾリン化合物及びその塩酸塩の結晶形 | |
| CN109311817B (zh) | 取代的含氮芳环化合物及其应用 | |
| EP3101020A1 (en) | Deuterated quinazolinone compound and pharmaceutical composition comprising same | |
| JP5161072B2 (ja) | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 | |
| CA3011289A1 (en) | Compounds for inhibiting cancer and virus | |
| JP2017509664A (ja) | チューブリンおよび複数の受容体阻害を有する置換二環式ピリミジン化合物 | |
| CN106146478B (zh) | 三嗪衍生物类间变性淋巴瘤激酶抑制剂 | |
| JP7018224B2 (ja) | 尿素置換芳香族環結合ジオキシノキノリン系化合物、その調製方法および使用 | |
| RU2021110277A (ru) | Наборы и способы для лечения онкологических заболеваний | |
| RU2605400C1 (ru) | ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2 | |
| RU2021101107A (ru) | Комбинация позиотиниба с цитотоксическим агентом и/или другим молекулярно-нацеленным агентом и ее использование |